Fast Five Quiz: Plaque Psoriasis Management

William James, MD


July 09, 2021

According to recent guidance from the National Psoriasis Foundation COVID-19 Task Force, a 2-week holiday from methotrexate may be considered for certain patients after COVID-19 vaccination with the Ad26.COV2.S [Johnson & Johnson] vaccine. The new guidance states: "Patients 60 or older who have at least one comorbidity associated with an increased risk for poor COVID-19 outcomes, and who are taking methotrexate with well-controlled psoriatic disease, may, in consultation with their prescriber, consider holding it for 2 weeks after receiving the Ad26.COV2.S [Johnson & Johnson] vaccine in order to potentially improve vaccine response." This recommendation does not apply to the mRNA vaccines produced by Pfizer and Moderna.

In many cases, plaque psoriasis responds better to a combination of topical and systemic therapy rather than to systemic treatment alone.

Patients with physically, psychologically, socially, or economically disabling disease may be considered candidates for systemic therapy. Systemic treatment should be initiated following failure of both topical treatments and phototherapy. In addition, systemic therapy should be considered for patients with active psoriatic arthritis

Learn more about the systemic agents used in the treatment of plaque psoriasis.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: